Jamshedpur Reporter

Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies – Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals

 Breaking News
  • No posts were found

Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies – Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals

May 04
20:15 2023
Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies - Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals
Persistent Epithelial Defect Market
DelveInsight’s ‘Persistent Epithelial Defect (PED) – Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight launched a new report on Persistent Epithelial Defect (PED) Market Insights, Epidemiology, and Market Forecast 2032.

DelveInsight’s ‘Persistent Epithelial Defect (PED) Market Report 2032’ report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Persistent Epithelial Disease Overview:

Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10–14 days after a corneal injury, even with standard supportive treatment. PED is defined as “defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses”. PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7–14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.

Persistent Epithelial Disease Epidemiology insights:

The total Incident population of Persistent Epithelial Defect (PED) in 7MM countries was estimated to be 238,058 cases in 2019.

Persistent Epithelial Disease Key Companies:

• Dompe Farmaceutici

 

• OcuNexus Therapeutics/Eyevance Pharmaceuticals

 

• Noveome Biotherapeutics

 

• RegeneRx Biopharmaceuticals

 

• Recordati Rare Diseases/Mimetech

 Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-market

Persistent Epithelial Disease Market Outlook

The Persistent Epithelial Defect (PED) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Persistent Epithelial Defect (PED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

The first step in the management of any epithelial abnormality is to determine the etiology of the disease. Currently, “bandage” methods are used to help re-epithelialize a cornea. The current approaches include Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Tetracyclines, prophylactic topical antibiotics and steroids. For the treatment of refractory cases, Amniotic membrane grafting, autologous serum, Scleral contact lenses, and others have been recommended. In severe cases, a conjunctival graft may be placed over the cornea. 

This section includes a glimpse of the Persistent Epithelial Defect market in 7MM. The market size of PED in the seven major markets was found to be USD xx million in 2019.

Table of contents

1 Key Insight

2 Executive Summary of Persistent Epithelial Defect (PED)

3 Persistent Epithelial Defect (PED) Market Overview at a Glance

4 Disease Background and Overview: Persistent Epithelial Defect (PED)

5 Case Reports

6 Persistent Epithelial Defect (PED) Epidemiology and Patient Population

7 United States Epidemiology

8 EU5 Epidemiology

9 Japan Epidemiology

10 Current Persistent Epithelial Defect (PED) Treatment and Medical Practices

11 Unmet needs

12 Persistent Epithelial Defect (PED) Marketed Drugs

13 Persistent Epithelial Defect (PED) Emerging Drugs

14 Persistent Epithelial Defect (PED) 7MM Market Analysis

15 United States

16 EU-5 countries: Market Outlook

17 Japan Market Outlook

18 Persistent Epithelial Defect (PED) Market Drivers

19 Persistent Epithelial Defect (PED) Market Barriers

20 SWOT Analysis

21 Reimbursement and market access

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Download Persistent Epithelial Defect Market Report 2032: https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories